SUNNYVALE, Calif., Oct. 15 /PRNewswire/ -- Scios Inc. (Nasdaq: SCIO)
announced today it has promoted Matthew R. Hooper to vice president, general
counsel. The Company also announced that John H. Newman has retired after
serving as general counsel since 1983.
Mr. Hooper, 44, has been at Scios for over a year as senior patent
counsel handling all intellectual property matters and drafting key contracts.
In his new role as a member of the corporate management committee, he will
oversee all legal aspects of the Company's operations.
"Matt's contributions over the past year were substantial as Scios made
the transition to a commercial-stage biotechnology company," said Richard B.
Brewer, Scios' president and chief executive officer. "His extensive legal
experience in the biopharmaceutical and other leading industries makes him
ideally suited to take over for John, who has played a major role in getting
us to where we are today. We are grateful for John's dedication and valuable
contributions over the years, and wish him well in his future endeavors."
Prior to joining Scios, Mr. Hooper was senior counsel in Jones Day Reavis
and Pogue's litigation group in Chicago, where he was responsible for
intellectual property due diligence activities for a variety of mergers and
acquisitions. Prior to that, he served for six years at Abbott Laboratories
in its patent and trademark department where he was responsible for patent
prosecution, due diligence and contract negotiation. Before joining Abbott,
Mr. Hooper spent nearly ten years as a patent attorney at Amoco Corporation.
He received his Juris Doctor from Northwestern University Law School and
his Bachelor of Science degree from LaSalle University.
Scios Inc.
Scios is a biopharmaceutical company developing novel treatments for
cardiovascular and inflammatory disease. The Company's disease-based
technology platform integrates expertise in protein biology with computational
and medicinal chemistry to identify novel targets and rationally design small
molecule compounds for large markets with unmet medical needs.
This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. We generally identify such forward-looking statements
using words like "believe," "intend," "expect," "may," "should," "plan,"
"project," "contemplate," "anticipate" or similar statements. Statements that
are not historical facts are forward-looking statements based on current
assumptions that involve risks and uncertainties. These risks and
uncertainties may include the sales penetration and success of Natrecor, the
success of clinical trials of our pipeline products, including SCIO-469, as
well as other risks detailed from time to time in the reports filed by Scios
with the SEC, including the Company's quarterly reports and annual report on
Form 10-K. Actual results, performance or achievements of Scios may differ
significantly from those described in these forward-looking statements. Scios
disclaims any intention or obligation to update or revise any financial
projections or forward-looking statements, whether as a result of new
information, future events or otherwise.
SOURCE Scios Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
investors, Wendy Carhart of Scios Inc.
+1-408-616-8325; or media, Jim Weiss of Weisscom +1-415-389-5055,
for Scios Inc.
|
